Advertisement
Coronavirus: UAE firm nears end of final trials of Chinese vaccine candidate
- ‘Early results are showing it is safe,’ CEO of G42 Healthcare says
- Trial is a partnership between China National Biotec Group and Abu Dhabi-based AI intelligence and cloud computing firm Group 42
Reading Time:2 minutes
Why you can trust SCMP
0
A United Arab Emirates company says it is nearing the end of phase three clinical trials of a Chinese Covid-19 vaccine candidate and hopes to manufacture it next year.
The trial, which began in mid-July, is a partnership between Sinopharm’s China National Biotec Group and Abu Dhabi-based artificial intelligence and cloud computing company Group 42 (G42).
The vaccine uses an inactivated virus – a well-known technology which has been used against diseases such as influenza and measles. Two doses are given.
It has been administered to more than 31,000 people in the UAE, Egypt, Bahrain and Jordan, G42 Healthcare chief executive Ashish Koshy said.
Results analysis and publication would happen in about two months, he said.
G42 had distribution and manufacturing agreements with Sinopharm and hoped to provide the UAE and other regional states with the vaccine, especially those that took part in the trial, Koshy said.
Advertisement